Canakinumab treatment in children with familial Mediterranean fever: report from a single center

In this study, we retrospectively evaluated 11 pediatric colchicine-resistant FMF patients who were t reated with canakinumab. Three of the patients had amyloidosis and two had uveitis. Based on our results, we suggest that canakinumab may be a safe and effective therapy in patients who are resistant to colchicine and even in the patients with amyloidosis. We also suggest that canakinumab might be a safe option for the patients with uveitis.
Source: Rheumatology International - Category: Rheumatology Source Type: research